Trial Arms and Cohorts

Treatment Arms

The below trial arms and cohorts are currently open to recruitment: 

Trial arms and cohorts currently open to recruitment
 ArmInvestigational Medicinal Products Cohort Number NSCLC HistologyMolecular Cohort
C Palbociclib – CDK-4/6 Inhibitor C1 SCC p16 (CDKN2A) loss of function with proficient Rb
    C3 NSCLC CDK4 amplification with proficient Rb
    C4 NSCLC CCND1 amplification with proficient Rb
    C5 NSCLC
  • STK11/LKB1 mutation or homozygous deletion, or TSC1/2 mutation AND
  • Activated KRAS/MAPK pathway i.e. concomitant KRAS, NRAS or NF1 mutation AND
  • Proficient Rb (no loss of Rb function either by mutation or deletion)
D Crizotinib – ALK Inhibitor D1 NSCLC MET amplification
    D3 NSCLC MET exon 14 skipping (splice mutation or deletion)
E Selumetinib – MEK Inhibitor & Docetaxel  E1  SCC  NF1 mutation 
    E2  ADC or NOS NSCLC NF1 mutation
    E3  NSCLC NRAS mutation
J AZD6738 – ATR inhibitor & Durvalumab - PD-L1 Inhibitor J1  NSCLC
  • KRAS mutation
  • STK11/LKB1 successful test result
    NAJ  NSCLC No actionable genetic change for other trial arms

The following trial Arms and Cohorts are now closed to recruitment:

Trial arms and cohorts closed to recruitment
 ArmInvestigational Medicinal Products Cohort Number NSCLC HistologyMolecular Cohort
A AZD4547 – FGFR Inhibitor A1 NSCLC FGFR2/3 mutation
B Vistusertib  – MTORC-1/2 Inhibitor B1 NSCLC TSC1/2 mutation
B Vistusertib  – MTORC-1/2 Inhibitor B2 NSCLC STK11/LKB1 mutation or homozygous deletion
C Palbociclib – CDK-4/6 Inhibitor C2 ADC or NOS NSCLC p16 (CDKN2A) loss of function with proficient Rb
    C6 NSCLC

KRAS mutation with proficient Rb

(No concomitant STK11/LKB1 mutation or deletion, no PIK3CA mutation or amplification, no PTEN mutation or homozygous deletion, no AKT mutation, no EGFR mutation, no FGFR2/3 mutation, no TSC1/2 mutation, and no HER2 mutation)
D Crizotinib – ALK Inhibitor D2 NSCLC ROS1 gene fusions
F AZD5363 - AKT Inhibitor F1 SCC PIK3CA mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations
    F2 SCC PIK3CA amplification & no KRAS, NF1, NRAS, HRAS or BRAF aberrations 
    F3 NSCLC

PIK3CA mutation or PIK3CA amplification & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (ADC or NOS NSCLC)

PTEN mutation or PTEN loss & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (ADC or NOS NSCLC)

AKT mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations (NSCLC)
    F4 SCC PTEN loss or PTEN mutation & no KRAS, NF1, NRAS, HRAS or BRAF aberrations
G Osimertinib – EGFR mutation positive T790M+ Inhibitor G1 NSCLC EGFR mutation & T790M mutation
H Sitravatinib – VEGFR inhibitor H1 NSCLC RET rearrangements
NA Durvalumab – PD-L1 Inhibitor NA1 NSCLC No actionable genetic change for other trial arms